Therefore, we suggest that bufalin inhibits CAMKK2 and affects ANXA2, subsequently impacting Wnt/β-catenin signaling pathway, promoting mitochondrial dysfunction, and inhibiting ICC proliferation and migration. Here, CAMKK2 is linked to intrahepatic cholangiocarcinoma.